Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel, June 17, 2024 HOLON, Israel, June 17, 2024 /PRNewswire/...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR...
Compugen Reports First Quarter 2024 Results PR Newswire HOLON, Israel, May 20, 2024 Enrollment completed and on track to present data from COM701...
U.S. index futures showed a slight uptick in Monday’s pre-market, buoyed by the Dow Jones closing above...
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential PR Newswire HOLON, Israel, May...
Compugen Appoints David Silberman as Chief Financial Officer PR Newswire HOLON, Israel, May 15, 2024 HOLON...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 PR Newswire HOLON, ISRAEL, May 6, 2024 HOLON, ISRAEL, May 6, 2024...
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel, April 10, 2024...
Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel, April 3, 2024 HOLON, Israel, April 3, 2024 /PRNewswire/...
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy PR Newswire HOLON, Israel, March 11, 2024 HOLON...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 PR Newswire HOLON, Israel, March 6, 2024 HOLON, Israel...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.